MedTrace Logo

Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers

NCT06408402 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1300

Last updated 2024-05-10

No results posted yet for this study

Summary

The primary objective of the PGL.EXPO-2 study is to test the hypothesis that exposure (occupational, environmental and/or domestic) to succinate dehydrogenase inhibitors (SDHi) could contribute to tumor emergence in subjects carrying a germline mutation in one of the SDHx genes.The primary endpoint will be the proportion of subjects (cases or controls) exposed to SDHi and the association with paraganglioma risk.

In addition, a blood sample (10 ml on EDTA) will be proposed to the participants to the study

Conditions

  • SDH-Related Familial Paraganglioma
  • SDHx-Related Syndromes
  • SDH Gene Mutation
  • Environmental Exposure

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • ANSES

    collaborator OTHER

  • Centre Leon Berard

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Anne-Paule Gimenez-Roqueplo, MD, PhD · Hôpital européen Georges Pompidou - APHP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2028-05-01
Completion
2028-05-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06408402 on ClinicalTrials.gov